Penwest Pharmaceuticals (PPCO) Set For Huge Fall
According to The Associated Press Endo Pharmaceuticals (ENDP). and Penwest Pharmaceuticals (PPCO). said Wednesday the patent on their pain drug Opana ER is being challenged by Impax Laboratories Inc. Endo and Penwest are currently reviewing the details of this notice…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
According to The Associated Press Endo Pharmaceuticals (ENDP). and Penwest Pharmaceuticals (PPCO). said Wednesday the patent on their pain drug Opana ER is being challenged by Impax Laboratories Inc.
Endo and Penwest are currently reviewing the details of this notice from IMPAX. Endo and Penwest note that they intend to pursue all available legal and regulatory avenues in defense of OPANA® ER, including enforcement of their intellectual property rights and approved labeling.
PPCO is off 31% in the pre-market at a 52-week low of $7.85.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.
